Recent developments in myelodysplastic syndromes

Blood

Volumn 124, Issue 18, 2014, Pages 2793-2803

  Bejar, Rafael ^a   Steensma, David P ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; GENETIC ANALYSIS; GENOMICS; HUMAN; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; PATHOGENESIS; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MYELODYSPLASTIC SYNDROMES;

BIOLOGICAL MARKER;

BIOLOGICAL MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS;

EID: 84908584242     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-04-522136     Document Type: Review

References (129)

1. Cazzola M, Della Porta MG, Malcovati L. The genetic basis of myelodysplasia and its clinical relevance. Blood. 2013; 122(25):4021-4034.
2. Garcia-Manero G. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol. 2014; 89(1): 97-108.
3. Tefferi A, Vardiman JW Myelodysplastic syndromes. N Engl J Med. 2009; 361(19): 1872-1885.
4. Vardiman JW, Thiele J, Arber D.A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114(5):937-951.
5. Walter MJ, Shen D, Ding L., et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med. 2012; 366(12): 1090-1098.
6. Ma X, Does M, Raza A., Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007; 109(8):1536-1542.
7. Cogle CR, Craig BM, Rollison D.E., List AF. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood. 2011; 117(26):7121-7125.
8. Goldberg SL, Chen E, Corral M., et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol. 2010; 28(17): 2847-2852.
9. Visser O, Trama A, Maynadié M, et al; RARECARE Working Group. Incidence, survival and prevalence of myeloid malignancies in Europe. Eur J Cancer. 2012; 48(17):3257-3266.
10. Chen B, Zhao WL, Jin J, et al Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries. Leukemia. 2005; 19(5):767-775.
11. Sekeres MA. The epidemiology of myelodysplastic syndromes. Hematol Oncol Clin North Am. 2010; 24(2):287-294.
12. Gologan R. Epidemiological data on myelodysplastic syndrome patients under 50 years in a single center of Romania. Leuk Res. 2010; 34(11):1442-1446.
13. Tsushima H, Iwanaga M, Miyazaki Y. Late effect of atomic bomb radiation on myeloid disorders: leukemia and myelodysplastic syndromes. Int J Hematol. 2012; 95(3):232-238.
14. Matsuda A, Germing U, Jinnai I., et al. Differences in the distribution of subtypes according to the WHO classification 2008 between Japanese and German patients with refractory anemia according to the FAB classification in myelodysplastic syndromes. Leuk Res. 2010; 34(8):974-980.
15. Iwanaga M, Hsu WL, Soda M, et al Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors. J Clin Oncol. 2011; 29(4):428-434.
16. Steensma DP. Dysplasia has A differential diagnosis: distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors. Curr Hematol Malig Rep. 2012; 7(4):310-320.
17. Valent P. Low blood counts: immune mediated, idiopathic, or myelodysplasia. Am Soc Hematol Educ Program. 2012:485-491.
18. Valent P, Bain BJ, Bennett J.M., et al. Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS. Leuk Res. 2012; 36(1):1-5.
19. Jacobs KB, Yeager M, Zhou W., et al. Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet. 2012; 44(6):651-658.
20. Mossner M, Nolte F, Hütter G, et al. Skewed X-inactivation patterns in ageing healthy and myelodysplastic haematopoiesis determined by a pyrosequencing based transcriptional clonality assay. J Med Genet. 2013; 50(2):108-117.
21. Laurie CC, Laurie CA, Rice K, et al Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet. 2012; 44(6): 642-650.
22. Holstege H, Pfeiffer W, Sie D., et al. Somatic mutations found in the healthy blood compartment of a 115-yr-old woman demonstrate oligoclonal hematopoiesis. Genome Res. 2014; 24(5):733-742.
23. Greenberg PL, Attar E, Bennett J.M., et al. Myelodysplastic syndromes: clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2013; 11(7):838-874.
24. Malcovati L, Hellström-Lindberg E, Bowen D, et al; European Leukemia Net. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013; 122(17):2943-2964.
25. Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2013. Available at: http://www.cibmtr.org. Accessed July 7, 2014.
26. Deeg HJ, de Lima M. Hematopoietic stem cell transplantation for older patients with myelodysplastic syndromes. J Natl Compr Canc Netw. 2013; 11(10):1227-1233.
27. Fenaux P, Adès L. How we treat lower-risk myelodysplastic syndromes. Blood. 2013; 121(21):4280-4286.
28. Dinmohamed AG, Visser O, van Norden Y, et al. Trends in incidence, initial treatment and survival of myelodysplastic syndromes: a population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010. Eur J Cancer. 2014; 50(5):1004-1012.
29. Sekeres MA, Schoonen WM, Kantarjian H, et al Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst. 2008; 100(21):1542-1551.
30. Steensma DP, Heptinstall KV, Johnson V.M., et al. Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey. Leuk Res. 2008; 32(5):691-698.
31. Dayyani F, Conley AP, Strom S.S., et al. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer. 2010; 116(9):2174-2179.
32. Steensma DP. Hematopoietic growth factors in myelodysplastic syndromes. Semin Oncol. 2011; 38(5):635-647.
33. Sekeres MA, Kantarjian H, Fenaux P., et al. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. Cancer. 2011; 117(5):992-1000.
34. Giagounidis A, Mufti GJ, Fenaux P, et al Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. Cancer. 2014; 120(12): 1838-1846.
35. Olnes MJ, Sloand EM Targeting immune dysregulation in myelodysplastic syndromes. JAMA. 2011; 305(8):814-819.
36. Steensma DP, Gattermann N. When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes? Best Pract Res Clin Haematol. 2013; 26(4):431-444.
37. Lyons RM, Marek BJ, Paley C, et al Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry. Leuk Res. 2014; 38(2):149-154.
38. Sekeres MA, Cutler C. How we treat higher-risk myelodysplastic syndromes. Blood. 2014; 123(6): 829-836.
39. Koreth J, Pidala J, Perez W.S., et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol. 2013; 31(21): 2662-2670.
40. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al; International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009; 10(3):223-232.
41. Steensma DP. Historical perspectives on myelodysplastic syndromes. Leuk Res. 2012; 36(12):1441-1452.
42. Van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G. Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature. 1974; 251(5474): 437-438.
43. Pedersen-Bjergaard J., Christiansen DH, Andersen M.K., Skovby F. Causality of myelodysplasia and acute myeloid leukemia and their genetic abnormalities. Leukemia. 2002; 16(11):2177-2184.
44. Pedersen-Bjergaard J., Andersen MK, Christiansen D.H., Nerlov C. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood. 2002; 99(6):1909-1912.
45. Kaneko H, Misawa S, Horiike S., Nakai H, Kashima K. TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities. Blood. 1995; 85(8):2189-2193.
46. Christiansen DH, Andersen MK, Desta F, Pedersen-Bjergaard J. Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia. 2005; 19(12):2232-2240.
47. Bejar R, Stevenson KE, Caughey B.A., et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2012; 30(27):3376-3382.
48. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011; 364(26):2496-2506.
49. Papaemmanuil E, Gerstung M, Malcovati L., et al; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013; 122(22):3616-3627, quiz 3699.
50. Haferlach T, Nagata Y, Grossmann V., et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014; 28(2):241-247.
51. Greenberg PL, Tuechler H, Schanz J., et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012; 120(12):2454-2465.
52. Schanz J, Tüchler H, Solé F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012; 30(8):820-829.
53. List A, Dewald G, Bennett J., et al; Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006; 355(14): 1456-1465.
54. Jerez A, Gondek LP, Jankowska A.M., et al. Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited. J Clin Oncol. 2012; 30(12):1343-1349.
55. Ebert BL, Pretz J, Bosco J., et al. Identification of RPS14 as a 5q-syndrome gene by RNA interference screen. Nature. 2008; 451(7176): 335-339.
56. Chen TH, Kambal A, Krysiak K., et al. Knockdown of Hspa9, a del(5q31.2) gene, results in a decrease in hematopoietic progenitors in mice. Blood. 2011; 117(5): 1530-1539.
57. Ye Y, McDevitt MA, Guo M, et al Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies. Cancer Res. 2009; 69(21): 8482-8490.
58. Kumar M, Narla A, Nonami A., et al. Coordinate loss of a microRNA Mir 145 and a protein-coding gene RPS14 cooperate in the pathogenesis of 5q-syndrome. Blood. 2011; 118(17):4666-4673.
59. Starczynowski DT, Kuchenbauer F, Argiropoulos B., et al. Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype. Nat Med. 2010; 16(1):49-58.
60. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009; 360(22):2289-2301.
61. Ernst T, Chase AJ, Score J, et al Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 2010; 42(8):722-726.
62. Nikoloski G, Langemeijer SMC, Kuiper RP, et al Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet. 2010; 42(8):665-667.
63. Gelsi-Boyer V., Trouplin V, Adélaïde J, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol. 2009; 145(6):788-800.
64. Tahiliani M, Koh KP, Shen Y, et al Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009; 324(5929):930-935.
65. Ko M, Huang Y, Jankowska A.M., et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature. 2010; 468(7325):839-843.
66. Mardis ER, Ding L, Dooling D.J., et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009; 361(11): 1058-1066.
67. Yan H, Parsons DW, Jin G, et al IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009; 360(8):765-773.
68. Ward PS, Patel J, Wise D.R., et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010; 17(3): 225-234.
69. Dang L, White DW, Gross S, et al Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009; 462(7274): 739-744.
70. Losman JA, Looper RE, Koivunen P, et al (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science. 2013; 339(6127):1621-1625.
71. Patel JP, Gönen M, Figueroa M.E., et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012; 366(12):1079-1089.
72. Ley TJ, Ding L, Walter M.J., et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010; 363(25):2424-2433.
73. Papaemmanuil E, Cazzola M, Boultwood J., et al; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011; 365(15): 1384-1395.
74. Wang L, Lawrence MS, Wan Y, et al SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011; 365(26): 2497-2506.
75. Quesada V, Conde L, Villamor N., et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet. 2012; 44(1): 47-52.
76. Yoshida K, Sanada M, Shiraishi Y., et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011; 478(7367):64-69.
77. Graubert TA, Shen D, Ding L., et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet. 2012; 44(1):53-57.
78. Walter MJ, Shen D, Shao J., et al. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia. 2013; 27(6):1275-1282.
79. Mufti GJ, Bennett JM, Goasguen J, et al; International Working Group on Morphology of Myelodysplastic Syndrome. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica. 2008; 93(11): 1712-1717.
80. Naqvi K, Jabbour E, Bueso-Ramos C, et al. Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood. 2011; 118(17):4690-4693.
81. Senent L, Arenillas L, Luño E, Ruiz J.C., Sanz G., Florensa L. Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes. Haematologica. 2013; 98(4): 568-575.
82. Gondek LP, Haddad AS, O'Keefe CL, et al. Detection of cryptic chromosomal lesions including acquired segmental uniparental disomy in advanced and low-risk myelodysplastic syndromes. Exp Hematol. 2007; 35(11): 1728-1738.
83. Heinrichs S, Kulkarni RV, Bueso-Ramos CE, et al. Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia. 2009; 23(9):1605-1613.
84. Kuznia S, Nadarajah N, Alpermann T., et al. Diagnostic and prognostic utility of a 26-gene panel for deep-sequencing mutation analysis in myeloid malignancies. Blood. 2013; 122(3):1547.
85. Couronné L, Bastard C, Bernard OA. TET2 and DNMT3A mutations in human T-cell lymphoma. N Engl J Med. 2012; 366(1):95-96.
86. Busque L, Patel JP, Figueroa M.E., et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet. 2012; 44(11):1179-1181.
87. Shlush LI, Zandi S, Mitchell A., et al; HALT Pan-Leukemia Gene Panel Consortium. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014; 506(7488): 328-333.
88. Kulasekararaj AG, Smith AE, Mian S.A., et al. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. Br J Haematol. 2013; 160(5):660-672.
89. Volkert S, Kohlmann A, Schnittger S., Kern W, Haferlach T, Haferlach C. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome. Genes Chromosomes Cancer. 2014; 53(5):402-410.
90. Saft L, Karimi M, Ghaderi M., et al. p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q). Haematologica. 2014; 99(6):1041-1049.
91. Jädersten M., Saft L, Smith A., et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol. 2011; 29(15):1971-1979.
92. Greenberg P, Cox C, LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89(6):2079-2088.
93. Steensma DP, Tefferi A. Risk-based management of myelodysplastic syndrome. Oncology (Williston Park). 2007; 21(1):43-54. Discussion 57-58, 62. Review.
94. Malcovati L, Della Porta MG, Strupp C, et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica. 2011; 96(10): 1433-1440.
95. Kantarjian H, O'Brien S, Ravandi F, et al Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008; 113(6):1351-1361.
96. Garcia-Manero G., Shan J, Faderl S., et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia. 2008; 22(3):538-543.
97. Schanz J, Steidl C, Fonatsch C., et al. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol. 2011; 29(15):1963-1970.
98. Mishra A, Corrales-Yepez M, Ali N.A., et al. Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. Am J Hematol. 2013; 88(7):566-570.
99. Breccia M, Salaroli A, Loglisci G., Alimena G. Revised IPSS (IPSS-R) stratification and outcome of MDS patients treated with azacitidine. Ann Hematol. 2013; 92(3):411-412.
100. Sekeres M, Swern A, Fenaux P., et al. P-104 outcomes by IPSS-R in lenalidomide-treated patients with IPSS low-/Int-1-risk MDS with del (5q) in MDS-003 and MDS-004: A retrospective analysis. Leuk Res. 2013; 37(SUPPL. 1):S69-S70.
101. Murphy DM, Bejar R, Stevenson K., et al. NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes. Leukemia. 2013; 27(10):2077-2081.
102. Hellström-Lindberg E., Gulbrandsen N, Lindberg G., et al; Scandinavian MDS Group. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin 1 granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol. 2003; 120(6):1037-1046.
103. Raza A, Reeves JA, Feldman E.J., et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008; 111(1):86-93.
104. Mallo M, Del Rey M, Ibáñez M, et al. Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. Br J Haematol. 2013; 162(1):74-86.
105. Itzykson R, Kosmider O, Cluzeau T., et al; Groupe Francophone des Myelodysplasies (GFM). Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011; 25(7):1147-1152.
106. Traina F, Visconte V, Elson P., et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia. 2014; 28(1):78-87.
107. Yang H, Bueso-Ramos C, DiNardo C., et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014; 28(6):1280-1288.
108. Sloand EM, Olnes MJ, Shenoy A, et al Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. J Clin Oncol. 2010; 28(35):5166-5173.
109. Saunthararajah Y, Nakamura R, Wesley R., Wang QJ, Barrett AJ. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood. 2003; 102(8):3025-3027.
110. Jerez A, Clemente MJ, Makishima H, et al STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. Blood. 2013; 122(14):2453-2459.
111. Lim ZY, Killick S, Germing U., et al. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia. 2007; 21(7): 1436-1441.
112. Passweg JR, Giagounidis AA, Simcock M, et al Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care - SAKK 33/99. J Clin Oncol. 2011; 29(3):303-309.
113. Kadia TM, Borthakur G, Garcia-Manero G, et al. Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol. 2012; 157(3):312-320.
114. Luger SM, Ringdén O, Zhang M.J., et al. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant. 2012; 47(2):203-211.
115. Platzbecker U, Wermke M, Radke J., et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia. 2012; 26(3):381-389.
116. Malcovati L, Papaemmanuil E, Ambaglio I., et al. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia [published online ahead of print June 26, 2014]. Blood. doi:10.1182/blood-2014-03-560227.
117. Ornstein MC, Sekeres MA Combination strategies in myelodysplastic syndromes. Int J Hematol. 2012; 95(1):26-33.
118. Sekeres MA, List AF, Cuthbertson D, et al Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J Clin Oncol. 2010; 28(13):2253-2258.
119. Silverman LR, Verma A, Odchimar-Reissig R, et al. A phase II trial of epigenetic modulators vorinostat in combination with azacitidine (azaC) in patients with the myelodysplastic syndrome (MDS): Initial results of study 6898 of the New York Cancer Consortium. Blood. 2013; 122:386.
120. Prebet T, Sun Z, Figueroa M.E., et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. J Clin Oncol. 2014; 32(12):1242-1248.
121. Prébet T., Gore SD, Esterni B, et al Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011; 29(24):3322-3327.
122. Garcia-Manero G., Fenaux P, Al-Kali A, et al. Randomized phase 3 study of intravenous rigosertib vs best supportive care (B) in higher-risk myelodysplastic syndrome (HR-MDS) patients (pts) after hypomethylating agent (HMA) failure: topline results. J Clin Oncol. Available at: http://investor.onconova.com/releasedetail.cfm?ReleaseID=826761. Accessed July 7, 2014.
123. Komrokji RS, Raza A, Lancet J.E., et al. Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes. Br J Haematol. 2013; 162(4):517-524.
124. Carrancio S, Markovics J, Wong P., et al. An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin. Br J Haematol. 2014; 165(6):870-882.
125. Bachegowda L, Gligich O, Mantzaris I., et al. Signal transduction inhibitors in treatment of myelodysplastic syndromes. J Hematol Oncol. 2013; 6:50.
126. Steensma DP, Komrokji RS, Stone R.M., et al. Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes. Cancer. 2014; 120(11):1670-1676.
127. Bejar R. Prognostic models in myelodysplastic syndromes. Am Soc Hematol. Educ Program. 2013; 2013:504-510.
128. Jabbour E, Garcia-Manero G, Xiao L., et al. Outcome of patients (pts) with low and intermediate-1 risk myelodysplastic syndrome (MDS) after hypomethylating agent (HMA) failure. Blood. 2013; 122:388.
129. Steensma DP, Stone RM Myelodysplastic syndromes. In: Goldman L, Schafer A, eds. Goldman's Cecil Medicine. 25th ed. New York: Elsevier; 2015.